Posted by Michael Wonder on 18 Jun 2020
FDA approves first therapy for rare disease that causes low phosphate blood levels, bone softening
18 June 2020 - Today, the U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumour-induced osteomalacia, a rare disease that is characterised by the development of tumours that cause weakened and softened bones.
The tumours associated with tumour-induced osteomalacia release a peptide hormone-like substance known as fibroblast growth factor 23 that lowers phosphate levels.
